Novel Biomarker and Cognate Therapeutic Targets for Precision Medicine in Heart Failure: Foundation of Innovation
Treatments for HF patients with reduced ejection fraction (HFrEF) have improved with newer agents, yet HF with preserved ejection fraction (HFpEF) and acute HF have neither effective treatments, nor disease specific biomarkers that could provide insight into the pathophysiological process or guidance for new therapies.
The TRANSFORM HF team will synergize the expertise and infrastructure across Canada to accelerate HF biomarker discovery, and to translate benefits directly to our patients and national economy. Three complementary and overlapping research themes will be pursued to answer the overarching question: Are new or existing biomarkers capable of precisely identifying underlying mechanisms and temporal stages o HFrEF, HFpEF and acute heart failure, including Indigenous and vulnerable populations?
"Work Package #1", Copyright © 2018 University Health Network. All rights reserved.
"Work Package #1, v.2", Copyright © 2018 University Health Network. All rights reserved.